These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 34704312

  • 1. Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
    Sakata S, Otsubo K, Yoshida H, Ito K, Nakamura A, Teraoka S, Matsumoto N, Shiraishi Y, Haratani K, Tamiya M, Ikeda S, Miura S, Tanizaki J, Omori S, Yoshioka H, Hata A, Yamamoto N, Nakagawa K.
    Cancer Sci; 2022 Jan; 113(1):221-228. PubMed ID: 34704312
    [Abstract] [Full Text] [Related]

  • 2. Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.
    Ishida M, Iwasaku M, Doi T, Ishikawa T, Tachibana Y, Sawada R, Ogura Y, Kawachi H, Katayama Y, Nishioka N, Morimoto K, Tokuda S, Yamada T, Takayama K.
    Cancer Sci; 2024 May; 115(5):1656-1664. PubMed ID: 38450844
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness Analysis of the Oncomine™ Dx Target Test MultiCDx System Using Next-generation Sequencing and Single-gene Test in Advanced and Recurrent Nonsquamous Non-small-cell Lung Cancer.
    Kohara T, Ikeda S, Ishikawa KB.
    JMA J; 2024 Jul 16; 7(3):375-386. PubMed ID: 39114611
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non-small cell lung cancer.
    Sakaguchi T, Iketani A, Furuhashi K, Nakamura Y, Suzuki Y, Ito K, Fujiwara K, Nishii Y, Katsuta K, Taguchi O, Hataji O.
    Thorac Cancer; 2021 Feb 16; 12(4):462-467. PubMed ID: 33314600
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis.
    Yu TM, Morrison C, Gold EJ, Tradonsky A, Layton AJ.
    Clin Lung Cancer; 2019 Jan 16; 20(1):20-29.e8. PubMed ID: 30243889
    [Abstract] [Full Text] [Related]

  • 7. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X, Zhao C, Li J, Su C, Chen X, Ren S, Li X, Zhou C.
    Cancer Med; 2019 Jun 16; 8(6):2858-2866. PubMed ID: 31016879
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. External Validation of ALK and ROS1 Fusions Detected Using an Oncomine Comprehensive Assay.
    Kim SW, DO SI, Na K.
    Anticancer Res; 2021 Sep 16; 41(9):4609-4617. PubMed ID: 34475089
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer.
    Amemiya K, Hirotsu Y, Nagakubo Y, Mochizuki H, Higuchi R, Tsutsui T, Kakizaki Y, Miyashita Y, Oyama T, Omata M.
    Cancer Cytopathol; 2021 Sep 16; 129(9):729-738. PubMed ID: 33872472
    [Abstract] [Full Text] [Related]

  • 14. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
    Dalal AA, Guerin A, Mutebi A, Culver KW.
    J Med Econ; 2018 Jul 16; 21(7):649-655. PubMed ID: 29516752
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
    Wu C, Zhao C, Yang Y, He Y, Hou L, Li X, Gao G, Shi J, Ren S, Chu H, Zhou C, Zhang J, Schmid-Bindert G.
    J Thorac Oncol; 2015 May 16; 10(5):778-783. PubMed ID: 25629635
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.